• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Stentys’ Apposition stent goes head-to-head against Medtronic’s Resolute | Studies Roundup

Stentys’ Apposition stent goes head-to-head against Medtronic’s Resolute | Studies Roundup

June 19, 2012 By MassDevice staff

Stentys logo

Stentys SA (EPA:STNT) is looking to prove its next-generation Apposition IV stent in a head-to-head study against Medtronic’s (NYSE:MDT) Resolute.

Stentys calls its suite of Apposition stents the "world’s 1st and only self-apposing stent to treat acute myocardial infarction," with a shape and size that adapts to "fit snugly" into blood vessels to prevent gaps that can lead to blood clots.

"Long-term malapposition of drug-eluting stents has been associated with late stent thrombosis, so this randomized trial with the new Stentys sirolimus-eluting self-apposing stent will be carefully followed by the community," co-principal investigator Dr. William Wijns said in prepared remarks. Wijns is also chairman of the European Assn. of Percutaneous Cardiovascular Interventions.

The Princeton, N.J.-based company will enroll 150 heart attack patients into a randomized, multi-center study will follow-up at 4 and 9 months.

Stentys expects to complete trial enrollment before the end of the year, with results available by the 2nd half of 2013 and CE Mark approval in the European Union in the 2nd half of 2014, according to a press release.

More medical device research & development news:

  • MIT researchers develop a fuel cell powered by the glucose in the human brain
  • Laparoscopic gastric bypass safer than open surgery, study finds
  • W.L. Gore launches quality improvement study for hernia repair mesh
  • CardioFocus touts HeartLight study finding 98% acute success in pulmonary isolation with single ablation procedure
  • Endosense closes enrollment in TactiCath force-sensing ablation catheter study
  • Svelte Medical launches Faaster post-market registry for its Svelte coronary stent
  • SalutarisMD presents latest data on Wet Age-related Macular Degeneration treatment with episcleral brachytherapy
  • Researchers associate erectile dysfunction with sleep apnea sufferers under the age of 60
  • CardiAQ touts 1st-in-human non-surgical percutaneous bioprosthetic mitral heart valve implant
  • ReCor Medical reports 6-month hypertension reduction with its Paradise ultrasound-based renal denervation system
  • Toshiba notes radiation dose reduction with AIDR 3D CT scanner
  • Titan Medical makes progress with its robotic single-site surgical platform in user study
  • Patients whose arteries re-close after stenting more than twice as likely to die within 7 years, UCLA researchers find
  • Lombard’s Aorfix endovascular stent works well in patients with complex neck anatomy

Filed Under: News Well, Research & Development, Stents Tagged With: Stentys

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy